ArticlePoultry science2026
Effects of recombinant Xylanase Xyn1m on growth performance, Intestinal morphology, and bacterial community structure in broilers.
Article in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated the effects of recombinant xylanase Xyn1m, derived from Fibrobacter succinogenes and expressed in Pichia pastoris, on growth performance, intestinal morphology, and gut microbial characteristics in broilers. A total of 144 one-day-old broilers were randomly allocated to three treatments with 12 replicates per treatment (4 birds per replicate): a control group (basal diet), a low-dose Xyn1m group (6,800 IU/kg), and a high-dose Xyn1m group (13,600 IU/kg). Supplementation with high-dose Xyn1m significantly increased body weight at 49 d and average daily gain during the 29-49 d growth phase compared with the control group (P< 0.01), whereas feed intake and feed conversion ratio were not affected. High-dose Xyn1m reduced duodenal crypt depth (P< 0.05), while ileal morphology remained unchanged. In the duodenum, Xyn1m supplementation increased the Shannon index and reduced the Simpson index of the microbial community (P< 0.05), although no significant differences were detected in the relative abundance of dominant bacterial taxa. Beta-diversity analysis showed that high-dose Xyn1m altered the duodenal microbial community structure. In contrast, no significant differences were observed in microbial diversity or community composition in the ileum, except for a linear reduction in the relative abundance of Acinetobacter (P< 0.05). Functional prediction using PICRUSt2 indicated enrichment of pathways associated with nutrient transport, carbohydrate metabolism, and energy production in the duodenal microbiota of the high-dose group, whereas predicted functional changes in the ileum were limited. These results indicate that dietary supplementation with 13,600 IU/kg recombinant xylanase Xyn1m improved growth performance during the mid-growth stage and enhanced duodenal microbial diversity and intestinal morphology, while exerting minimal effects on distal ileal microbial functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.